Galecto, Inc. (NASDAQ: GLTO), a biotech company specializing in pioneering cancer and fibrosis treatments, has reached a significant milestone in its clinical journey. They've initiated an investigator-led Phase 2 trial at the Earle A. Chiles Research Institute (EACRI), part of the Providence Cancer Institute in Portland, Oregon, USA.

Galecto，Inc.（纳斯达克股票代码：GLTO）是一家专门从事开创性癌症和纤维化治疗的生物技术公司，在其临床旅程中取得了重大里程碑。他们在美国俄勒冈州波特兰的普罗维登斯癌症研究所（Providence Cancer Institute）的Earle A.Chiles Research Institute（EACRI）启动了一项由研究者主导的2期临床试验。

Led by Dr. Brendan Curti and Dr. William Redmond, the trial will evaluate GB1211, Galecto’s oral galectin-3 inhibitor, in combination with pembrolizumab for treating metastatic malignant melanoma (MM) and head and neck squamous cell carcinoma (HNSCC). Supported by a grant from the National Cancer Institute, Galecto is supplying GB1211 for the trial.The trial stems from galectin-3's overexpression in various cancers, including melanoma and HNSCC, which correlates with tumor progression and resistance to treatments like pembrolizumab and atezolizumab.

由Brendan Curti博士和William Redmond博士领导，该试验将评估Galecto口服半乳糖凝集素-3抑制剂GB1211与pembrolizumab联合治疗转移性恶性黑色素瘤（MM）和头颈部鳞状细胞癌（HNSCC）。在国家癌症研究所的资助下，Galecto正在为该试验提供GB1211。该试验源于半乳糖凝集素-3在各种癌症（包括黑色素瘤和HNSCC）中的过度表达，这与肿瘤进展和对pembrolizumab和atezolizumab等治疗的耐药性相关。

GB1211 aims to mitigate these resistance mechanisms by inhibiting galectin-3.Building upon promising Phase 1b/2a trial results, Galecto aims to explore GB1211's potential in combination with pembrolizumab further. Dr. Curti emphasizes the strength of Providence Cancer Institute's research approach, citing insights from Dr.

GB1211旨在通过抑制半乳糖凝集素-3来减轻这些耐药机制。基于有希望的1b/2a期试验结果，Galecto旨在进一步探索GB1211与pembrolizumab联合的潜力。柯蒂博士强调了普罗维登斯癌症研究所研究方法的优势，引用了博士的见解。

Redmond’s lab as crucial for this trial.Dr. Redmond highlights their research into galectin-3's role in tumor immune suppression, expressing enthusiasm for countering ICI resistance with GB1211 and pembrolizumab.Galecto's CEO, Dr. Hans Schambye, lauds the trial's initiation at Providence Cancer Institute, recognizing Dr.

雷蒙德的实验室对这项试验至关重要。Redmond博士强调了他们对半乳糖凝集素-3在肿瘤免疫抑制中的作用的研究，表达了用GB1211和pembrolizumab对抗ICI耐药性的热情。Galecto的首席执行官Hans Schambye博士赞扬了普罗维登斯癌症研究所启动的这项试验。

Redmond's expertise and anticipating synergistic benefits from combining GB1211 with pembrolizumab.The Phase 2 trial, a randomized, double-blind placebo-controlled endeavor, aims to evaluate GB1211's impact on pembrolizumab's response rate in metastatic melan.

Redmond的专业知识以及将GB1211与pembrolizumab结合的预期协同效益。第二阶段试验是一项随机，双盲，安慰剂对照的研究，旨在评估GB1211对pembrolizumab在转移性黑色素瘤中的反应率的影响。